H. Mackay

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial

P. Pollock, C. Genestie, H. Kitchener, 2022, Modern Pathology.

Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry

C. Genestie, H. Mackay, A. Fyles, 2022, British Journal of Cancer.

Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program

J. Ledermann, T. Bosse, N. Singh, 2022, International Journal of Gynecological Cancer.

Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.

P. Pollock, H. Kitchener, T. Bosse, 2017, Gynecologic oncology.

595 Implementation of collaborative translational research (TransPORTEC) findings in an international endometrial cancer clinical trials program (RAINBO)

T. Bosse, L. Mileshkin, N. Horeweg, 2021, Endometrial cancer.

397 Molecular profiling of NSMP high-risk endometrial cancers of the PORTEC-3 trial – prognostic refinement and druggable targets

A. Leary, N. Horeweg, P. Bessette, 2021, Endometrial cancer.